Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Chief Financial Officer | May 05, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 283,460 |
Reported balance
After 2026-05-05 transaction · row 1
1 source rowRow 1 · 2026-05-05 · Tax withholding · Disposed 92,652 · Balance 283,460 F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2026 Filed May 7, 2026 21:33 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 92,652 | $4.18 | $387,285.36 |
DisclosureSEC source: 0001214659-26-005749 · marketforms-73071.xml · nonDerivative · entry 1 TOTH A ERNEST JR · CIK 0001280273 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,460 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 16:51 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 58,254 | $4.17 | $243,093.94 |
DisclosureSEC source: 0001214659-26-003143 · marketforms-72470.xml · nonDerivative · entry 2 TOTH A ERNEST JR · CIK 0001280273 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,112 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $4.17 to $4.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 16:51 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001214659-26-003143 · marketforms-72470.xml · derivative · entry 3 TOTH A ERNEST JR · CIK 0001280273 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-03-09 F4 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 16:51 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 95,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-003143 · marketforms-72470.xml · nonDerivative · entry 1 TOTH A ERNEST JR · CIK 0001280273 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,366 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 09, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 8,736 | $2.65 | $23,150.40 |
DisclosureSEC source: 0001214659-25-004226 · marketforms-68575.xml · nonDerivative · entry 3 TOTH A ERNEST JR · CIK 0001280273 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,366 F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001214659-25-004226 · marketforms-68575.xml · derivative · entry 4 TOTH A ERNEST JR · CIK 0001280273 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-03-07 F3 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 10,193 | $2.65 | $27,011.45 |
DisclosureSEC source: 0001214659-25-004226 · marketforms-68575.xml · nonDerivative · entry 2 TOTH A ERNEST JR · CIK 0001280273 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,102 F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-004226 · marketforms-68575.xml · nonDerivative · entry 1 TOTH A ERNEST JR · CIK 0001280273 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,295 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2025 Filed Apr 13, 2026 19:52 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantPerformance Stock Units · Derivative | 82,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-004594 · marketforms-72932.xml · derivative · entry 1 TOTH A ERNEST JR · CIK 0001280273 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2028-03-07 F1 · security: This Form 4 was filed late due to an inadvertent administrative oversight. F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period). F2 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period). Read SEC document |
| March 09, 2024 Filed Mar 12, 2024 17:47 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 11,705 | $4.88 | $57,120.40 |
DisclosureSEC source: 0001214659-24-004392 · marketforms-65148.xml · nonDerivative · entry 1 TOTH A ERNEST JR · CIK 0001280273 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,295 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 14:36 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $5.68 | $0.00 |
DisclosureSEC source: 0001214659-24-004308 · marketforms-64694.xml · derivative · entry 2 TOTH A ERNEST JR · CIK 0001280273 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-03-07 F2 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 14:36 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-004308 · marketforms-64694.xml · nonDerivative · entry 1 TOTH A ERNEST JR · CIK 0001280273 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,000 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantPerformance Stock Units · Derivative | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-010923 · marketforms-61879.xml · derivative · entry 1 TOTH A ERNEST JR · CIK 0001280273 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2026-05-05 F1 · derivative.exercise_price: Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. F1 · derivative.exercise_date: Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. Read SEC document |
| May 05, 2023 Filed May 5, 2023 20:00 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantPerformance Stock Units · Derivative | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-006559 · marketforms-61241.xml · derivative · entry 1 TOTH A ERNEST JR · CIK 0001280273 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2026-05-05 F1 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. F1 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. Read SEC document |
| March 09, 2023 Filed Mar 9, 2023 20:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 140,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-003688 · marketforms-59530.xml · nonDerivative · entry 1 TOTH A ERNEST JR · CIK 0001280273 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 15:21 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001214659-22-013278 · marketforms-57374.xml · derivative · entry 1 TOTH A ERNEST JR · CIK 0001280273 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-11-04 F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 15:26 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001214659-22-003899 · marketforms-55765.xml · derivative · entry 1 TOTH A ERNEST JR · CIK 0001280273 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-03-10 F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 22:51 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 120,000 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001214659-21-006718 · marketforms-53154.xml · derivative · entry 1 TOTH A ERNEST JR · CIK 0001280273 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option to purchase Common Stock of the Issuer under the Issuer's 2018 Equity Incentive Plan (the "Plan"). Said options vest over a three-year period, with 25% of such option vesting on each of the one-year and two-year anniversaries of the option vesting commencement date and the remaining 50% vesting on the third-year anniversary of the option vesting commencement date, provided that at the relevant vesting date, the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan. The option expires ten years after the date of grant. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 21:10 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001214659-21-003153 · marketforms-51882.xml · derivative · entry 1 TOTH A ERNEST JR · CIK 0001280273 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2031-03-11 F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.